[go: up one dir, main page]

MX2009005641A - Sales de 3-(3-amino-2-(r)-hidroxi-propil)-1-(4-fluoro-fenil)-8-(8- metil-naftalen-1-ilmetil)-1,3,8-triaza-espiro[4,5]deca n-4-ona. - Google Patents

Sales de 3-(3-amino-2-(r)-hidroxi-propil)-1-(4-fluoro-fenil)-8-(8- metil-naftalen-1-ilmetil)-1,3,8-triaza-espiro[4,5]deca n-4-ona.

Info

Publication number
MX2009005641A
MX2009005641A MX2009005641A MX2009005641A MX2009005641A MX 2009005641 A MX2009005641 A MX 2009005641A MX 2009005641 A MX2009005641 A MX 2009005641A MX 2009005641 A MX2009005641 A MX 2009005641A MX 2009005641 A MX2009005641 A MX 2009005641A
Authority
MX
Mexico
Prior art keywords
triaza
decan
naphthalen
ylmethyl
spiro
Prior art date
Application number
MX2009005641A
Other languages
English (en)
Inventor
Frank J Villani
Steven J Mehrman
Armin Roessler
Roger Faessler
Hegyi Jean Francois Alexandre Lucas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39145092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009005641(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009005641A publication Critical patent/MX2009005641A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención está dirigida a sales de 3-(3-amino-2-(R)- hidroxi-propil)-1 -(4-fluoro-fenil)-8-(8-metil-naftalen-1 -ilmetil)-1 ,3,8-triaza- espiro[4.5]decan-4-ona, composiciones farmacéuticas que las contienen, y su uso en el tratamiento de trastornos y condiciones moduladas por NOP, por ejemplo depresión, ansiedad, abuso del alcohol, etcétera; además, la presente invención está dirigida a procedimientos para la preparación de 3-(3-amino-2- (R)-hidroxi-propil)-1 -(4-fluoro-fenil)-8-(8-metil-naftalen-1 -ilmetil)-1 ,3,8-triaza- espiro[4.5]decan-4-ona y sus sales correspondientes.
MX2009005641A 2006-11-28 2007-11-14 Sales de 3-(3-amino-2-(r)-hidroxi-propil)-1-(4-fluoro-fenil)-8-(8- metil-naftalen-1-ilmetil)-1,3,8-triaza-espiro[4,5]deca n-4-ona. MX2009005641A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86137806P 2006-11-28 2006-11-28
PCT/US2007/084642 WO2008067167A1 (en) 2006-11-28 2007-11-14 Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one

Publications (1)

Publication Number Publication Date
MX2009005641A true MX2009005641A (es) 2009-06-05

Family

ID=39145092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005641A MX2009005641A (es) 2006-11-28 2007-11-14 Sales de 3-(3-amino-2-(r)-hidroxi-propil)-1-(4-fluoro-fenil)-8-(8- metil-naftalen-1-ilmetil)-1,3,8-triaza-espiro[4,5]deca n-4-ona.

Country Status (19)

Country Link
US (1) US8703948B2 (es)
EP (1) EP2102206B1 (es)
JP (1) JP5727139B2 (es)
KR (1) KR20090083954A (es)
CN (2) CN103202840B (es)
AR (1) AR063982A1 (es)
AU (1) AU2007325355A1 (es)
CA (1) CA2670858C (es)
CL (1) CL2007003406A1 (es)
CR (1) CR10898A (es)
EA (1) EA200970517A1 (es)
EC (1) ECSP099365A (es)
IL (1) IL198793A0 (es)
MX (1) MX2009005641A (es)
NO (1) NO20092416L (es)
PE (1) PE20081300A1 (es)
TW (1) TW200838862A (es)
UY (1) UY30746A1 (es)
WO (1) WO2008067167A1 (es)

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155699A (en) * 1960-03-30 1964-11-03 Mobay Chemical Corp Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3238216A (en) * 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
US3839340A (en) * 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro{8 4.5{9 decanes
US3629267A (en) * 1968-10-28 1971-12-21 Smith Kline French Lab Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione
US3859340A (en) * 1970-09-09 1975-01-07 Squibb & Sons Inc ' -methylfluorene-2-acetic acid
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
JPS54109983A (en) * 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
US4329363A (en) * 1978-09-08 1982-05-11 Merck & Co., Inc. Substituted mercapto acid amides and their use
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS57212180A (en) * 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
WO1988000190A1 (en) 1986-06-25 1988-01-14 Massachusetts Institute Of Technology Optically active derivatives of glycidol
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4135473A1 (de) * 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
EP0661972A1 (en) 1991-12-27 1995-07-12 Beth Israel Hospital Use of spiperone or spiperone derivatives as immunosuppressant agents
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
JPH11500100A (ja) 1993-09-09 1999-01-06 サイオス ノバ インコーポレイテッド 偽ペプチドおよび非ペプチドブラジキニンレセプターアンタゴニスト
US5739336A (en) * 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
ES2214604T3 (es) 1996-03-29 2004-09-16 Pfizer Inc. Derivados de la 6-fenilpiridil-2-amina.
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
DE69803653T2 (de) * 1997-12-05 2002-08-29 F. Hoffmann-La Roche Ag, Basel 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
EP0921125B1 (en) 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
WO1999059997A1 (en) 1998-05-18 1999-11-25 Novo Nordisk A/S Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
DK0970957T3 (da) * 1998-06-12 2001-12-03 Hoffmann La Roche Diaza-spiro[3.5]nonan-derivativer
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
DE69923744T2 (de) 1998-10-23 2006-02-23 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten
CO5150149A1 (es) 1998-11-20 2002-04-29 Smithkline Beecham Spa Composiciones farmaceuticas derivadas de quinolina
JP2000169476A (ja) 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
AU1382901A (en) 1999-11-17 2001-05-30 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
DE19956598A1 (de) 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
JP3989247B2 (ja) 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
AU2001262729A1 (en) 2000-06-14 2001-12-24 Banyu Pharmaceutical Co., Ltd 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
MXPA03009239A (es) * 2001-04-10 2004-11-12 Johnson & Johnson Derivados de 1,3,8-triazapiro[4,5]decan-4-ona utiles para el tratamiento de trastornos mediados por el receptor orl-1.
JP4342181B2 (ja) 2001-04-18 2009-10-14 ユーロ−セルティーク エス．エイ． スピロピラゾール化合物
US20030078278A1 (en) * 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
JP4356453B2 (ja) * 2001-07-23 2009-11-04 萬有製薬株式会社 ４−オキソイミダゾリジン−２−スピロピペリジン誘導体
US20040014955A1 (en) * 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
WO2003064425A1 (en) * 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
EP1601674B1 (en) * 2002-09-09 2012-08-08 Janssen Pharmaceutica NV Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2006023852A2 (en) * 2004-08-19 2006-03-02 Vertex Pharmaceuticals, Incorporated Modulators of muscarinic receptors
CN101227903A (zh) * 2005-06-02 2008-07-23 詹森药业有限公司 用作orl-1受体调节剂的新型3-螺环吲哚基衍生物
US20080200492A1 (en) 2006-11-28 2008-08-21 Vaidya Anil H Methods for the treatment of alcohol abuse, addiction and dependency
CN101679430B (zh) 2007-04-09 2013-12-25 詹森药业有限公司 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物
US20100076003A1 (en) 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators

Also Published As

Publication number Publication date
CN101622254A (zh) 2010-01-06
CR10898A (es) 2009-10-30
EP2102206B1 (en) 2015-04-08
WO2008067167A1 (en) 2008-06-05
CA2670858C (en) 2015-01-13
CN103202840B (zh) 2015-02-11
IL198793A0 (en) 2010-02-17
CN103202840A (zh) 2013-07-17
KR20090083954A (ko) 2009-08-04
AU2007325355A1 (en) 2008-06-05
TW200838862A (en) 2008-10-01
JP5727139B2 (ja) 2015-06-03
EP2102206A1 (en) 2009-09-23
ECSP099365A (es) 2009-06-30
US20080176882A1 (en) 2008-07-24
US8703948B2 (en) 2014-04-22
UY30746A1 (es) 2008-05-31
CA2670858A1 (en) 2008-06-05
CN101622254B (zh) 2013-05-29
PE20081300A1 (es) 2008-09-17
EA200970517A1 (ru) 2009-12-30
CL2007003406A1 (es) 2008-08-22
AR063982A1 (es) 2009-03-04
NO20092416L (no) 2009-08-21
JP2010511054A (ja) 2010-04-08

Similar Documents

Publication Publication Date Title
MX2009011006A (es) Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion.
EA201300620A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK
MY146972A (en) Novel compounds as opioid receptor modulators.
MX2009004060A (es) Moduladores de proteina cinasa de triazolpiridazina.
EP2526933A3 (en) Inhibitors of bruton's tyrosine kinase
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
GB201104267D0 (en) Pyrrolopyridineamino derivatives
MY144293A (en) Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
PL2041133T3 (pl) Pochodne imidazo[1,2-a]pirydyno-2-karboksamidów, ich wytwarzanie i zastosowanie terapeutyczne
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
TW200613305A (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CL2008003578A1 (es) Compuestos derivados de imidazo[1,5-a]-quinoxalina, inhibidores pde10; composicion farmaceutica que los comprende y/o kit; procedimiento de preparacion de estos; y su uso en el tratamiento de enfermedades snc
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
UA86617C2 (en) 2-(1-AZA-BICYCLO[2.2.2]OCT-3-YL)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4-ONE DERIVATIVES AS LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
PL1778680T3 (pl) Spirocykliczne pochodne cykloheksanu
ATE446089T1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
GB0327380D0 (en) Method
EA201270629A1 (ru) Новые полиморфные формы метил(4,6-диамино-2-[1-(2-фторбензил)-1h-пиразоло[3,4-b]пиридин-3-ил]пиримидин-5-ил)карбамата
NZ600593A (en) Novel (heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors
SI1730147T1 (sl) Substituirane triazaspiro dekan onskespojine za zdravljenje obezitete
MX2009005641A (es) Sales de 3-(3-amino-2-(r)-hidroxi-propil)-1-(4-fluoro-fenil)-8-(8- metil-naftalen-1-ilmetil)-1,3,8-triaza-espiro[4,5]deca n-4-ona.
WO2010033451A3 (en) 5-oxazolidin-2-one substituted 1,3,8-triazaspiro [4.5] decan-4-one derivatives useful as orl-1 receptor modulators
PH12013501938A1 (en) 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators

Legal Events

Date Code Title Description
FG Grant or registration